Taking control of castleman disease: Leveraging precision medicine technologies to accelerate rare disease research

Samantha Kass Newman, Raj K. Jayanthan, Grant W. Mitchell, Jossie A. Carreras Tartak, Michael P. Croglio, Alexander Suarez, Amy Y. Liu, Beatrice M. Razzo, Enny Oyeniran, Jason R. Ruth, David C. Fajgenbaum

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Castleman disease (CD†) is a rare and heterogeneous disorder characterized by lymphadenopathy that may occur in a single lymph node (unicentric) or multiple lymph nodes (multicentric), the latter typically occurring secondary to excessive proinflammatory hypercytokinemia. While a cohort of multicentric Castleman disease (MCD) cases are caused by Human Herpes Virus-8 (HHV-8), the etiology of HHV-8 negative, idiopathic MCD (iMCD), remains unknown. Breakthroughs in “omics” technologies that have facilitated the development of precision medicine hold promise for elucidating disease pathogenesis and identifying novel therapies for iMCD. However, in order to leverage precision medicine approaches in rare diseases like CD, stakeholders need to overcome several challenges. To address these challenges, the Castleman Disease Collaborative Network (CDCN) was founded in 2012. In the past 3 years, the CDCN has worked to transform the understanding of the pathogenesis of CD, funded and initiated genomics and proteomics research, and united international experts in a collaborative effort to accelerate progress for CD patients. The CDCN’s collaborative structure leverages the tools of precision medicine and serves as a model for both scientific discovery and advancing patient care.

Original languageEnglish (US)
Pages (from-to)383-388
Number of pages6
JournalYale Journal of Biology and Medicine
Volume88
Issue number4
StatePublished - Dec 2015
Externally publishedYes

Fingerprint

Giant Lymph Node Hyperplasia
Precision Medicine
Rare Diseases
Medicine
Technology
Research
Lymph Nodes
Viruses
Genomics
Proteomics
Patient Care

Keywords

  • Castleman disease
  • Genomics
  • Interleukin-6
  • Lymphoproliferative disorder
  • Orphan disease
  • Precision medicine
  • Rare disease

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Newman, S. K., Jayanthan, R. K., Mitchell, G. W., Carreras Tartak, J. A., Croglio, M. P., Suarez, A., ... Fajgenbaum, D. C. (2015). Taking control of castleman disease: Leveraging precision medicine technologies to accelerate rare disease research. Yale Journal of Biology and Medicine, 88(4), 383-388.

Taking control of castleman disease : Leveraging precision medicine technologies to accelerate rare disease research. / Newman, Samantha Kass; Jayanthan, Raj K.; Mitchell, Grant W.; Carreras Tartak, Jossie A.; Croglio, Michael P.; Suarez, Alexander; Liu, Amy Y.; Razzo, Beatrice M.; Oyeniran, Enny; Ruth, Jason R.; Fajgenbaum, David C.

In: Yale Journal of Biology and Medicine, Vol. 88, No. 4, 12.2015, p. 383-388.

Research output: Contribution to journalReview article

Newman, SK, Jayanthan, RK, Mitchell, GW, Carreras Tartak, JA, Croglio, MP, Suarez, A, Liu, AY, Razzo, BM, Oyeniran, E, Ruth, JR & Fajgenbaum, DC 2015, 'Taking control of castleman disease: Leveraging precision medicine technologies to accelerate rare disease research', Yale Journal of Biology and Medicine, vol. 88, no. 4, pp. 383-388.
Newman, Samantha Kass ; Jayanthan, Raj K. ; Mitchell, Grant W. ; Carreras Tartak, Jossie A. ; Croglio, Michael P. ; Suarez, Alexander ; Liu, Amy Y. ; Razzo, Beatrice M. ; Oyeniran, Enny ; Ruth, Jason R. ; Fajgenbaum, David C. / Taking control of castleman disease : Leveraging precision medicine technologies to accelerate rare disease research. In: Yale Journal of Biology and Medicine. 2015 ; Vol. 88, No. 4. pp. 383-388.
@article{af466344b8574746ab87827ca4030b6d,
title = "Taking control of castleman disease: Leveraging precision medicine technologies to accelerate rare disease research",
abstract = "Castleman disease (CD†) is a rare and heterogeneous disorder characterized by lymphadenopathy that may occur in a single lymph node (unicentric) or multiple lymph nodes (multicentric), the latter typically occurring secondary to excessive proinflammatory hypercytokinemia. While a cohort of multicentric Castleman disease (MCD) cases are caused by Human Herpes Virus-8 (HHV-8), the etiology of HHV-8 negative, idiopathic MCD (iMCD), remains unknown. Breakthroughs in “omics” technologies that have facilitated the development of precision medicine hold promise for elucidating disease pathogenesis and identifying novel therapies for iMCD. However, in order to leverage precision medicine approaches in rare diseases like CD, stakeholders need to overcome several challenges. To address these challenges, the Castleman Disease Collaborative Network (CDCN) was founded in 2012. In the past 3 years, the CDCN has worked to transform the understanding of the pathogenesis of CD, funded and initiated genomics and proteomics research, and united international experts in a collaborative effort to accelerate progress for CD patients. The CDCN’s collaborative structure leverages the tools of precision medicine and serves as a model for both scientific discovery and advancing patient care.",
keywords = "Castleman disease, Genomics, Interleukin-6, Lymphoproliferative disorder, Orphan disease, Precision medicine, Rare disease",
author = "Newman, {Samantha Kass} and Jayanthan, {Raj K.} and Mitchell, {Grant W.} and {Carreras Tartak}, {Jossie A.} and Croglio, {Michael P.} and Alexander Suarez and Liu, {Amy Y.} and Razzo, {Beatrice M.} and Enny Oyeniran and Ruth, {Jason R.} and Fajgenbaum, {David C.}",
year = "2015",
month = "12",
language = "English (US)",
volume = "88",
pages = "383--388",
journal = "Yale Journal of Biology and Medicine",
issn = "0044-0086",
publisher = "Yale Journal of Biology and Medicine Inc.",
number = "4",

}

TY - JOUR

T1 - Taking control of castleman disease

T2 - Leveraging precision medicine technologies to accelerate rare disease research

AU - Newman, Samantha Kass

AU - Jayanthan, Raj K.

AU - Mitchell, Grant W.

AU - Carreras Tartak, Jossie A.

AU - Croglio, Michael P.

AU - Suarez, Alexander

AU - Liu, Amy Y.

AU - Razzo, Beatrice M.

AU - Oyeniran, Enny

AU - Ruth, Jason R.

AU - Fajgenbaum, David C.

PY - 2015/12

Y1 - 2015/12

N2 - Castleman disease (CD†) is a rare and heterogeneous disorder characterized by lymphadenopathy that may occur in a single lymph node (unicentric) or multiple lymph nodes (multicentric), the latter typically occurring secondary to excessive proinflammatory hypercytokinemia. While a cohort of multicentric Castleman disease (MCD) cases are caused by Human Herpes Virus-8 (HHV-8), the etiology of HHV-8 negative, idiopathic MCD (iMCD), remains unknown. Breakthroughs in “omics” technologies that have facilitated the development of precision medicine hold promise for elucidating disease pathogenesis and identifying novel therapies for iMCD. However, in order to leverage precision medicine approaches in rare diseases like CD, stakeholders need to overcome several challenges. To address these challenges, the Castleman Disease Collaborative Network (CDCN) was founded in 2012. In the past 3 years, the CDCN has worked to transform the understanding of the pathogenesis of CD, funded and initiated genomics and proteomics research, and united international experts in a collaborative effort to accelerate progress for CD patients. The CDCN’s collaborative structure leverages the tools of precision medicine and serves as a model for both scientific discovery and advancing patient care.

AB - Castleman disease (CD†) is a rare and heterogeneous disorder characterized by lymphadenopathy that may occur in a single lymph node (unicentric) or multiple lymph nodes (multicentric), the latter typically occurring secondary to excessive proinflammatory hypercytokinemia. While a cohort of multicentric Castleman disease (MCD) cases are caused by Human Herpes Virus-8 (HHV-8), the etiology of HHV-8 negative, idiopathic MCD (iMCD), remains unknown. Breakthroughs in “omics” technologies that have facilitated the development of precision medicine hold promise for elucidating disease pathogenesis and identifying novel therapies for iMCD. However, in order to leverage precision medicine approaches in rare diseases like CD, stakeholders need to overcome several challenges. To address these challenges, the Castleman Disease Collaborative Network (CDCN) was founded in 2012. In the past 3 years, the CDCN has worked to transform the understanding of the pathogenesis of CD, funded and initiated genomics and proteomics research, and united international experts in a collaborative effort to accelerate progress for CD patients. The CDCN’s collaborative structure leverages the tools of precision medicine and serves as a model for both scientific discovery and advancing patient care.

KW - Castleman disease

KW - Genomics

KW - Interleukin-6

KW - Lymphoproliferative disorder

KW - Orphan disease

KW - Precision medicine

KW - Rare disease

UR - http://www.scopus.com/inward/record.url?scp=84948689731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948689731&partnerID=8YFLogxK

M3 - Review article

C2 - 26604862

AN - SCOPUS:84948689731

VL - 88

SP - 383

EP - 388

JO - Yale Journal of Biology and Medicine

JF - Yale Journal of Biology and Medicine

SN - 0044-0086

IS - 4

ER -